ClinicalTrials.gg
CompletedNCT00920764Updated Jun 6, 2018

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

A Phase 2 interventional study of Placebo for Atrasentan 0.2 mg/mL solution and 0.25 mg Atrasentan QD in Chronic Kidney Disease and Diabetic Nephropathy, sponsored by AbbVie (prior sponsor, Abbott). Completed at 28 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Renal Insufficiency, Chronic by AbbVie — none open to participants now, none under way, none of them phase 3. Renal Insufficiency, Chronic · AbbVie.

Enrollment
4th of 12
92 · median 62
Started
2009
the only one that year
Phase 2
4 of 19
none open now
Registered
4th of 19
by date

Among the 19 studies in Renal Insufficiency, Chronic by AbbVie, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 2, and was the 4th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 19 studies in Renal Insufficiency, Chronic by AbbVie is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Renal Insufficiency, Chronic by AbbVie as a file.
02

Study summary

The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.

Patients with Type 2 diabetes with nephropathy must be receiving a renin-angiotensin system inhibitor, such as an Angiotensin converting enzyme inhibitor (ACEi) or an Angiotensin II Receptor Blocker (ARB) for participation in this study. ACEi and ARB treatment are the standard of care for the management of proteinuria in Chronic Kidney Disease (CKD) patients.

03

Conditions studied

  • Chronic Kidney Disease
  • Diabetic Nephropathy

Keywords

  • CKD Stages 3&4
  • Endothelin antagonist
  • Proteinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Subject is >= 18 years old.
  • 2.Subject has voluntarily signed and dated an form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.
  • 3.Subject has Type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Phase.
  • 4.Subject has been receiving a stable dose (i.e., same type and regimen) of angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin receptor blocking agents (ARB) for at least 2 months prior to the Screening Phase.
  • 5.If female, subject must be not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). The reason for non-childbearing potential must be specified in the subject's eCRF.
  • 6.If male, subject must be surgically sterile or if sexually active and of childbearing potential, the site must document the lack of desire for future procreation and subject must agree to use a condom and a second reliable barrier of from the Screening Visit through two months following completion of their participation in the study.
  • 7.For entry into the Treatment Phase the subject must satisfy the following criteria based on Screening laboratory values:

    • a.Estimated > 20 mL/min/1.73 m2 by simplified MDRD formula
    • b.UACR between 100 and 3000 mg/g as determined at the initial Screening visit or by the mean of the 2 morning void urine specimens obtained prior to the second Screening visit.
    • c.Serum albumin > 3.0 g/dL.
    • d. \<= 10%.
    • e.Pro-BNP \<= 500pg/mL.
    • f.Negative urine pregnancy test for female subjects.

Exclusion criteria

Exclusion Criteria:

  • 1.Subject has a history of significant peripheral edema (2 + or greater), or facial edema unrelated to trauma, or a history of myxedema in the 6 months prior to Screening.
  • 2.Subject receiving loop diuretics > 30 mg BID of furosemide or > 0.5 mg BID of bumetanide or > 25 mg BID of ethacrynic acid.
  • 3.Subject has a history of pulmonary edema.
  • 4.Subject has a history of pulmonary hypertension, , emphysema, pulmonary fibrous disease, asthma or other lung disease that requires oxygen.
  • 5.Subject has a documented history of heart failure, defined as (NYHA) Class II, III or IV heart failure.
  • 6.Subject has a (BMI) > 40.
  • 7.Subject has elevated liver enzymes ( and/or AST) > 1.5 x the (ULN).
  • 8.Subject has a \< 9.5 g/dL.
  • 9.Subject has a history of an allergic reaction or significant sensitivity to atrasentan or its .
  • 10.Subject has a history of a chronic gastrointestinal disease, which in the Investigator's opinion may cause significant GI malabsorption.
  • 11.Subject has a history of secondary hypertension (i.e., renal artery stenosis, primary aldosteronism or pheochromocytoma).
  • 12.Subject has poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and or diastolic blood pressure ≥ 90 mmHg) or hypotension (systolic blood pressure \<= 90 mmHg).
  • 13.Subject has significant comorbidities (e.g., advanced , advanced liver disease) with a less than 1 year.
  • 14.Subject is expected to receive an increased dose of current RAAS inhibitor (ACEi, ARB, renin or aldosterone inhibitor) during the course of the study. Conversions from one product to another (e.g., ACEi to ARB) must be at equivalent doses.
  • 15.Subject has coronary artery disease (CAD) within 3 months prior to the Screening Period, defined as one of the following:

    • Hospitalization for MI or unstable angina; or
    • New onset angina with positive functional study or coronary angiogram revealing stenosis; or
    • Coronary revascularization procedure.
  • 16.Subject has a history of viral or bacterial infection within 4 weeks of Screening or infection.
  • 17.Subject has scheduled or planned surgery with general anesthesia within 12 weeks of Screening Visit.
  • 18.Subject has a history of drug or alcohol abuse within 6 months prior to the Screening Visit.
  • 19.Subject has evidence of poor compliance with diet or medication that may interfere, in the Investigator's opinion, with adherence to the protocol.
  • 20.Subject has received any drug within 30 days prior to study drug administration.
  • 21.For any reason, subject is considered by the Investigator to be an unsuitable candidate to receive atrasentan oral solution or is put at risk by study procedures
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Active comparator
    A

    Drug: 1.75 mg Atrasentan QD

  • Active comparator
    B

    Drug: 0.25 mg Atrasentan QD

  • Active comparator
    C

    Drug: 0.75 mg Atrasentan QD

  • Placebo comparator
    D

    Drug: Placebo for Atrasentan 0.2 mg/mL solution

Interventions

  • DrugPlacebo for Atrasentan 0.2 mg/mL solution

    10 mL oral solution, daily, 8 weeks

  • Drug0.25 mg Atrasentan QD

    10 mL oral solution, daily, 8 weeks

  • Drug0.75 mg Atrasentan QD

    10 mL oral solution, daily, 8 weeks

  • Drug1.75 mg Atrasentan QD

    10 mL oral solution, daily, 8 weeks

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to each post-baseline observation on UACR over the course of treatment period versus standard of care

    Time frame: Week 8 visit or final assessment

Secondary outcomes

  1. Proportion of subjects achieving at least a 25% reduction in final UACR levels from baseline

    Time frame: Week 8 visit or final assessment

  2. Proportion of subjects achieving at least a 40% reduction in final UACR levels from baseline

    Time frame: Week 8 visit or final assessment

  3. Change from baseline to the final value in UACR, estimated glomerular filtration rate (eGFR), Neutrophil Gelatinase-Associated Lipocalin (NGAL)

    Time frame: Week 8 visit or final assessment

  4. Change from baseline to each weekly measurement in NGAL

    Time frame: Week 8 visit or final assessment

07

Study locations

28 sites
  • Site Reference ID/Investigator# 19386
    Tempe, Arizona 85284, United States
  • Site Reference ID/Investigator# 25043
    Azusa, California 91702, United States
  • Site Reference ID/Investigator# 23308
    Los Angeles, California 90022, United States
  • Site Reference ID/Investigator# 25430
    Los Angeles, California 90048, United States
  • Site Reference ID/Investigator# 20421
    San Diego, California 92123, United States
  • Site Reference ID/Investigator# 22442
    San Diego, California 92123, United States
  • Site Reference ID/Investigator# 21061
    Whittier, California 90603, United States
  • Site Reference ID/Investigator# 16572
    Yuba City, California 95991, United States
  • Site Reference ID/Investigator# 26142
    Coral Gables, Florida 33134, United States
  • Site Reference ID/Investigator# 16567
    Hudson, Florida 34667, United States
  • Site Reference ID/Investigator# 16577
    Pembroke Pines, Florida 33028, United States
  • Site Reference ID/Investigator# 25242
    Pembroke Pines, Florida 33028, United States
  • Site Reference ID/Investigator# 16569
    Rockville, Maryland 20852, United States
  • Site Reference ID/Investigator# 16574
    Omaha, Nebraska 68131, United States
  • Site Reference ID/Investigator# 20221
    Buffalo, New York 14215, United States
  • Site Reference ID/Investigator# 16576
    Greenville, North Carolina 27834, United States
  • Site Reference ID/Investigator# 16573
    Morehead City, North Carolina 28557, United States
  • Site Reference ID/Investigator# 26143
    Statesville, North Carolina 28625, United States
  • Site Reference ID/Investigator# 19383
    Bethlehem, Pennsylvania 18017, United States
  • Site Reference ID/Investigator# 26365
    Orangeburg, South Carolina 29115, United States
  • Site Reference ID/Investigator# 16571
    San Antonio, Texas 78229-4801, United States
  • Site Reference ID/Investigator# 16566
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator# 19384
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator# 24542
    Fairfax, Virginia 22030, United States
  • Site Reference ID/Investigator# 16564
    Las Piedras, 00771, Puerto Rico
  • Site Reference ID/Investigator# 19381
    Ponce, 00717, Puerto Rico
  • Site Reference ID/Investigator# 16563
    San Juan, 00918, Puerto Rico
  • Site Reference ID/Investigator# 16562
    San Juan, 00936-5067, Puerto Rico
08

References and documents

Publications

  • Perez-Gomez MV, Sanchez-Nino MD, Sanz AB, Martin-Cleary C, Ruiz-Ortega M, Egido J, Navarro-Gonzalez JF, Ortiz A, Fernandez-Fernandez B. Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. PubMed 26239562 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2009
First posted
Jun 15, 2009
Start
Jun 2009
Primary completionActual
Apr 2010
CompletionActual
May 2010
Results delay requested
Aug 18, 2011
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00920764
Responsible party
Sponsor
First posted
Jun 15, 2009
Start date
Jun 2009
Primary completion
Apr 2010
Completion
May 2010
Last update
Jun 6, 2018

Study contacts

Dennis Andress
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion